Growing use of generic drugs to boost the growth of Acute Bacterial Skin And Skin Structure Infections Market

Acute Bacterial Skin And Skin Structure Infections Market


The global Acute Bacterial Skin And Skin Structure Infections Market is estimated to be valued at US$ 3674.6 Mn in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
The acute bacterial skin and skin structure infections market involves antibiotics such as cephalosporins, carbapenems, fluoroquinolones, lipoglycopeptides, oxazolidinones, and tetracyclines that are used in the treatment of bacterial infections of the skin and skin structures. Some common acute bacterial skin and skin structure infections include cellulitis, erysipelas, and cutaneous abscesses. These infections spread rapidly and require emergency medical care and antibiotics treatment. The generic form of drugs represents a major cost-effective treatment option for such infections, thus fueling market growth.

Market key trends:
One of the key trends witnessed in the acute bacterial skin and skin structure infections market size is the growing preference and utilization of generic drugs over branded drugs due to their cost effectiveness. Generics account for nearly 90% of all prescriptions filled in the U.S. Currently. The patent expiration of many blockbuster drugs has led to the availability of lower-cost generics. For instance, the generic version of linezolid is available at nearly 80% lower price than branded Zyvox. This has significantly increased the access and adoption of acute infection treatment regimens globally.
Porter's Analysis

Threat of new entrants: The threat of new entrants is moderate due to high capital requirements and established brand loyalty of existing players in the market.

Bargaining power of buyers: The bargaining power of buyers is high due to the presence of many established brands and generic drugs available in the market.

Bargaining power of suppliers: The bargaining power of suppliers is moderate as there are many suppliers of raw materials available.

Threat of new substitutes: The threat of substitutes is low as there are limited treatment options available for acute bacterial skin and skin structure infections.

Competitive rivalry: High due to the presence of many established brands.

Key Takeaways

The global acute bacterial skin and skin structure infections market is expected to witness high growth, exhibiting a CAGR of 6.0% over the forecast period, due to increasing resistance to antibiotics.

North America is expected to dominate the global acute bacterial skin and skin structure infections market owing to the increasing incidences of antibiotic resistance. Asia Pacific is anticipated to exhibit the fastest growth rate during the forecast period due to rising healthcare expenditures.

Key players operating in the acute bacterial skin and skin structure infections market include Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Sandoz Inc., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Paratek Pharmaceuticals, Inc.